{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Mid+Norfolk&uin=212635", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?answer.answeringMemberConstituency=Mid+Norfolk&uin=212635", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Mid+Norfolk&uin=212635&_metadata=all", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&answer.answeringMemberConstituency=Mid+Norfolk&uin=212635", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Mid+Norfolk&uin=212635", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?answer.answeringMemberConstituency=Mid+Norfolk&uin=212635", "items" : [{"_about" : "http://data.parliament.uk/resources/101774", "AnsweringBody" : [{"_value" : "Department for Business, Innovation and Skills"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/101774/answer", "answerText" : {"_value" : "

The UK pharmaceutical sector contributes more than £13 billion to UK Gross Value Added (GVA), making it the second largest in Europe after Germany measured by GVA. The life sciences sector employs 173,900 people in the UK, and the UK is second only to the US measured by the share of top 1% citations in life science related subjects. The Office of Life Sciences is currently developing a set of indicators reflecting the broad competitiveness of the UK life science environment against key international comparators.<\/p>

<\/p>

More broadly, the most recent Global Competitiveness Report by the World Economic Forum (WEF) overall ranks the UK within the top 10 competitive countries in which to conduct business, continuing its historical strong performance. The UK is well regarded for its high quality science and research base, high-level skills, openness to international trade and effectiveness of its regulatory and competition regimes and flexible labour market. As a result the UK overall remains a magnet for inward investment, second only to the USA.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2014-11-11", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2014-11-11T12:46:09.8147047Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "26"} , "answeringDeptShortName" : {"_value" : "Business, Innovation and Skills"} , "answeringDeptSortName" : {"_value" : "Business, Innovation and Skills"} , "date" : {"_value" : "2014-10-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Biotechnology"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Business, Innovation and Skills, what comparative assessment he has made of the competitiveness of the (a) UK, (b) France, (c) Germany, (d) China and (e) US life science industry.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4051", "label" : {"_value" : "Biography information for John Glen"} } , "tablingMemberConstituency" : {"_value" : "Salisbury"} , "tablingMemberPrinted" : [{"_value" : "John Glen"} ], "uin" : "212635"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }